Icatibant

FirazyrImmune/Anti-inf

Evidence grade

AFDA-approved Rx (labeled use)

Cardiovascular · 0–5 · separate axis

Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeImmune / Inflammatory

MechanismBradykinin B2 receptor antagonist; blocks the mediator driving hereditary angioedema attacks

EffectsTreats an attack in progress rather than preventing one

Dosing30 mg SC as a single dose; may repeat per prescribing information

Bottom lineStrongest data when used for its labeled indication under clinician guidance.

Batches on filenone

No tested batches on file.

Read with10

VIP ARA-290 Semaglutide Tirzepatide Liraglutide Exenatide Dulaglutide Pramlintide Cagrilintide Retatrutide

Cautions & interactions

Injection-site reactions are near-universal; laryngeal attacks still require emergency care

May reduce the antihypertensive effect of ACE inhibitors; discuss with the prescribing clinician.

CV 1 of 5 — No adverse cardiovascular signal at labelled use; bradykinin blockade is theoretically relevant to ACE-inhibitor effects.